VIDEO: Advancements in the pipeline for psoriatic arthritis

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

I'm very excited about the dual inhibitor to say the least, considering the dermatological results published in The New England Journal of Medicine. I am also excited to have additional R23 inhibitors and then there are some interesting new mechanisms such as the MK-2 inhibitor. I need to read more about this, so I'm gonna stop here but it looks like this pipeline continues to renew itself so that's very, very exciting for us.

And again, I would say that the wonderful part of this, is the experience that we have had in our other diseases, rheumatoid arthritis and ulcerative colitis, you can in your psoriatic arthritis clinic and I can when I'm seeing patients with psoriatic arthritis take that experience forward and have a good sense of how to use these medications and what to talk to our patients about as we make a shared decision, use these medications for them, but kind of with some experience in the rheumatology world already.

And Dr. Haques, I think I would be so excited to see that these pipelines would develop more in parallel, as opposed, it feels like a medication is developed for a certain disease and then if it's not that great it's recycled in another disease, I just wish there would be simultaneous innovation so that we save time. I hope in the future, we're going to see more of this.

I would say you're so right about that, Dr. Orbai. We hope to, you know, as we understand the mechanisms better that drive these diseases that we are focusing on treatment strategies and treatment modalities where we are moving things forward and parallel.